SEC 13F Intelligence

Bahl & Gaynor Inc / ABT

Bahl & Gaynor Inc’s Abbott Laboratories Position

Does Bahl & Gaynor Inc own Abbott Laboratories (ABT)? Yes — 766.9K shares worth $79M (+0.40% of its 13F portfolio) as of Q1 2026, down from 892.9K shares the prior filed quarter.

Position Value
$79M
Q1 2026
Shares
766.9K
% of Portfolio
+0.40%
Quarters Held
30
currently held

Position History ABT

Reported value by quarter
Q4 ’18: $238MQ4 ’18Q1 ’19: $236MQ2 ’19: $255MQ3 ’19: $258MQ4 ’19: $269MQ4 ’19Q1 ’20: $225MQ2 ’20: $260MQ3 ’20: $306MQ4 ’20: $300MQ4 ’20Q1 ’21: $321MQ2 ’21: $311MQ3 ’21: $316MQ4 ’21: $366MQ4 ’21Q1 ’22: $237MQ2 ’22: $283MQ3 ’22: $268MQ4 ’22: $279MQ4 ’22Q1 ’23: $279MQ2 ’23: $273MQ3 ’23: $200MQ4 ’23: $199MQ4 ’23Q1 ’24: $205MQ2 ’24: $146MQ3 ’24: $117MQ4 ’24: $112MQ4 ’24Q1 ’25: $128MQ2 ’25: $132MQ3 ’25: $120MQ4 ’25: $112MQ4 ’25Q1 ’26: $79Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026766.9K$79M+0.40%
Q4 2025892.9K$112M+0.57%
Q3 2025897.5K$120M+0.60%
Q2 2025969.1K$132M+0.67%
Q1 2025966.9K$128M+0.65%
Q4 2024990.5K$112M+0.59%
Q3 20241.03M$117M+0.60%
Q2 20241.40M$146M+0.81%
Q1 20241.80M$205M+1.14%
Q4 20231.81M$199M+1.20%
Q3 20232.07M$200M+1.28%
Q2 20232.50M$273M+1.66%
Q1 20232.75M$279M+1.50%
Q4 20222.54M$279M+1.74%
Q3 20222.77M$268M+1.77%
Q2 20222.60M$283M+1.86%
Q1 20222.00M$237M+1.74%
Q4 20212.60M$366M+2.05%
Q3 20212.68M$316M+1.94%
Q2 20212.69M$311M+1.90%
Q1 20212.68M$321M+2.03%
Q4 20202.74M$300M+1.91%
Q3 20202.82M$306M+2.17%
Q2 20202.85M$260M+1.96%
Q1 20202.85M$225M+1.96%
Q4 20193.09M$269M+1.86%
Q3 20193.08M$258M+1.86%
Q2 20193.03M$255M+1.89%
Q1 20192.95M$236M+2.17%
Q4 20183.29M$238M+2.54%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Bahl & Gaynor Inc’s full portfolio or all institutional holders of ABT.